KAT6A: A Protein Involved in Protein Synthesis and A Potential Drug Target

Target Name: KAT6A

NCBI ID: G7994

KAT6A

KAT6A: A Protein Involved in Protein Synthesis and A Potential Drug Target

KAT6A, also known as Lysine acetyltransferase 6A, is a gene that encodes a protein involved in the process of protein synthesis. The protein produced by this gene is known as KAT6A, which is a key enzyme in the 60S ribosome complex, a critical protein synthesizing machine in the cell. KAT6A is often used as a drug target or biomarker due to its unique structure and function.

The 60S ribosome complex is responsible for synthesizing the majority of the proteins that are produced in the cell. This complex is composed of several subunits, including the alpha and beta subunits, which are responsible for the amino acid side chain synthesis and the transfer of the amino acids to the 30S subunit, respectively. KAT6A is one of the proteins that is synthesized by the alpha subunit of the 60S ribosome complex.

KAT6A is a 24.5 kDa protein that contains 215 amino acid residues. The protein has a unique structure that is composed of a catalytic active site, a nucleotide binding site, and a C-terminus. The catalytic active site is located at the center of the protein and is responsible for the substrate binding and the catalytic activity. The nucleotide binding site is located at the base pairs 12-18 amino acids from the catalytic active site and is responsible for the binding of the nucleotides. The C-terminus is located at the end of the protein and is responsible for the stability and localization of the protein.

KAT6A is often used as a drug target due to its unique structure and function. The catalytic active site of KAT6A makes it an attractive target for small molecules that can inhibit the protein's activity. Additionally, the protein's unique structure and function make it difficult to predict the structure of any potential inhibitors. This makes it difficult to design drugs that specifically target KAT6A and avoid harming other proteins in the cell.

KAT6A has also been used as a biomarker for various diseases, including cancer. The expression of KAT6A has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that KAT6A may be a useful biomarker for the diagnosis and treatment of cancer. Additionally, the regulation of KAT6A has been shown to be involved in various cellular processes, including cell growth, apoptosis, and autophagy. This suggests that KAT6A may be a useful target for drugs that aim to modulate these processes.

In conclusion, KAT6A is a unique and fascinating protein that is involved in the 60S ribosome complex. Its catalytic active site and unique structure make it an attractive target for small molecules that can inhibit its activity. Additionally, its function as a biomarker for various diseases and its involvement in cellular processes make it a valuable tool for the diagnosis and treatment of cancer. As a result, KAT6A is a potential drug target and biomarker for various diseases.

Protein Name: Lysine Acetyltransferase 6A

Functions: Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML

The "KAT6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KAT6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets